Search

L’acquisizione del sistema pronominale dell’italiano da parte di apprendenti non nativi costituisce un elemento significativo sul piano della ricerca, vista la sostanziale carenza di letteratura scientifica a riguardo. Il contributo propone l’analisi di alcuni dati sulla presenza della proforma “ne”, in un campione di apprendenti stranieri, a un anno di distanza dall’esperienza di studio o di lavoro in Italia. I risultati della ricerca, condotta sulla base delle risposte a un questionario e della costruzione di un corpus testuale, ne confermano le sequenze di acquisizione. The functions of the “ne” clitic in post-basic interlanguages of Italian L2 learners one year after immersion in an italian-speaking context The acquisition of the pronominal system of Italian by non-native learners is a significant element in terms of research, given the substantial lack of scientific literature in this regard. The paper analyzes some data regarding the presence of the clitic “ne”, in a sample of foreign learners, one year after study or work experience in Italy. The results of the research, based on a questionnaire, confirm the acquisition sequences., Italiano LinguaDue, V. 11 N. 2 (2019)

In E. Bonetto, M. J. Ennis, & D. Unterkofler (Eds.), Teaching languages for specific and academic purposes in higher education ��� English, Deutsch, Italiano (pp. 127���140).

Publisher's version (útgefin grein)., Aims: To estimate the incidence of direct oral anticoagulant drug (DOAC) use in patients with nonvalvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries. Methods: Longitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed. Results: A total of 186 405 new DOAC users (age ≥18 years) were identified. Standardized incidences varied from 1.93–2.60 and 0.11–8.71 users/10 000 (2011–2015) for dabigatran and rivaroxaban, respectively, and from 0.01–8.12 users/10 000 (2012–2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10 000 inhabitants in SIDIAP (Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only 1 database includes the total reference population (DNR) while others are considered a population representative sample (CPRD, BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4% (SIDIAP) and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in AOK Nordwest (Germany). Conclusion: Overall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There was variability in patient characteristics such as comorbidities, potentially interacting drugs and dose adjustment. (EMA/2015/27/PH)., The research leading to these results was conducted as part of the activities of the PE‐PV Consortium (Pharmacoepidemiology and Pharmacovigilance Consortium), which is a public academic partnership coordinated by the University of Utrecht. The project has received support from the European Medicines Agency under the Framework service contract (nr EMA/2015/27/PH) with regard to the reopening of competition no3. K. Janhsen (Witten/Herdecke University, Alfred‐Herrhausen‐ Straße 50, 58448 Witten, Germany (UW/H)) and B. Grave (AOK NORDWEST, Kopenhagener Straße 1, 44269 Dortmund, Germany). R. Gerlach and M. Tauscher (National Association of Statutory Health Insurance Physicians of Bavaria, Elsenheimerstr. 39, D‐80687 Munich, Germany). The authors of the BIFAP database would like to acknowledge the excellent collaboration of the primary care general practitioners and pediatricians, and also the support of the regional governments to the database. This study is based in part on data from the BIFAP fully financed by the Spanish Agency on Medicines and Medical Devices (AEMPS). The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the EMA (European Medicines Agency) or one of its committees or working parties, or AEMPS (Agencia Española de Medicamentos y Productos Sanitarios).

EL.LE

Studi e ricerche